anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peripherally inserted central catheters, or PICC lines, are clinically used for many years in the treatment of patients, whereby the implantation occurs under x-ray/fluoroscopy. Female and male patients of legal age that have the medical indication for Power-PICC-Line catheter implantation can be screened for the study. These medical indications include the necessity of chemotherapy in the course of an oncological treatment or parenteral nutrition. The study objective is to test the efficacy and safety of the SHERLOCK system, evaluated by a monocentric, randomized-controlled study. The advantage for the participating patients lies in a reduced radiation exposure due to the discontinued final chest x-ray examination (fluoroscopy). Furthermore, the SHERLOCK system can be deployed directly on ward, at the patient's bedside leading to a cost and time saving. Recruited in- and outpatients (of legal age) with indication for Power-PICC-Line catheter implantation will be randomly assigned to one of the two arms (fluoroscopy or SHERLOCK). Depending on randomization, the Power-PICC implantation occurs either under fluoroscopy or with the SHERLOCK system. All related substances, measures or procedures are performed according to the clinical routine. The medical device is a fully integrated magnetic tracking and ECG-based peripherally inserted central catheter (PICC) tip confirmation technology applied on patients with normal sinus rhythm and placed through a peripheral vein. The Sherlock system is CE-certified since December 2011.

The referral of patients with indication to PICC-Line implantation at the institute of diagnostic and interventional radiology occurs through different departments of the University Hospital Jena. The patients are registered for radiological treatment and checked again by a radiologist if a PICC-Line implantation is indicated. If this is the case, the radiologist conducts an informed consent discussion with the patient about possible complications and risks during intervention and informs him also about a possible study. After signature of the written informed consent, the patient is included. On the intervention day, the patient is randomly assigned to one of the two study arms through RandomTool (Sherlock vs. fluoroscopy). According to randomization group, the PICC catheter is implanted (duration: 30 minutes) and eventually a chest x-ray (fluoroscopy) is performed to assess safety and efficacy.The intervention time from puncture to catheter placement is documented. After intervention, the patient is transferred back to the ward or sent home in hemodynamically stable conditions. The examination of the puncture site before discharge is performed by a ward physician or by the family doctor. 24 h after PICC-Line implantation, the treating physician is contacted and questioned about possible complications (catheter occlusion, haematoma, infection of the puncture site, arm vein thrombosis, pain, etc.), that are then thoroughly documented.
Participants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.
The radial forearm fasciocutaneous free flap (hereafter referred to as RFFF) was described more than 30 years ago as a fasciocutaneous flap for microsurgical transfer. It was soon after established as a safe and reliable flap for transfer of fascia and cutaneous tissue. Currently, it is used to repair any defect in which a relatively thin island of skin is needed with a fascial strength layer . While the flap itself is very reliable, it leaves a donor site that can be very unsightly and has multiple known complications including loss of pronation, pain, paresthesias, cold intolerance, and skin graft necrosis. The donor site is typically covered with a split thickness skin graft (hereafter referred to as STSG). In an effort to minimize these complications, several groups have described a technique of placing Integra© dermal substitute (hereafter referred to as Integra) underneath the STSG to provide a thicker support and decrease overall morbidity associated with the defect. These studies have shown success in decreasing overall morbidity including increasing range of motion and improving aesthetic quality of the donor site. However, the largest study to date has included only 29 subjects. Furthermore, these studies do not provide a comparative cohort of subjects repaired with a classic STSG to show effectiveness of this technique when compared to a classic repair. Our goal is to perform a prospective study comparing subjects repaired with a classic STSG and those repaired with one step Integra and STSG applied at the same time. These subjects will be evaluated for overall donor site aesthetic quality and functional outcome as described below.
The present invention relates to a nucleic acid aptamer, and in particular relates to a nucleic acid aptamer H7 for targeted inhibition of vibrio anguillarum having a nucleic acid sequence shown as SEQ. NO.1. The present invention also relates to use of the nucleic acid aptamer H7 in preparation of a vibrio anguillarum inhibitor. In the present invention, vibrio anguillarum is the target, and the aptamer (H7) screened by a Cell-SELEX technology is selected to analyze the antibacterial function thereof on vibrio anguillarum. The nucleic acid aptamer H7 has the functions of short screening period, simple and convenient chemical synthesis, and being able to replace antibiotics, and has a good application prospect. The present invention provides a theoretical basis for further development of studies on inhibitory aptamers.
While the excessive inflammation in cancer cachexia is well-known to be induced by the overproduction of inflammatory mediators in the periphery, microflora disruption and brain dysfunction are also considered to contribute to the induction of cancer cachexia. Hypothalamic microglia play a crucial role in brain inflammation and central-peripheral immune circuits via the production of inflammatory mediators. In the present study, we evaluated possible changes in excessive secretion of gut microbiota-derived endotoxin and the expression timeline of several inflammation-regulatory mediators and their inhibiting modulators in hypothalamic microglia of a mouse model of cancer cachexia following transplantation of pancreatic cancer cells. We demonstrated that the plasma level of lipopolysaccharide (LPS) was significantly increased with an increase in anaerobic bacteria, especially Firmicutes, in the gut at the late stage of tumor-bearing mice that exhibited dramatic appetite loss, sarcopenia and severe peripheral immune suppression. At the early stage, in which tumor-bearing mice had not yet displayed "cachexia symptoms", the mRNA expression of pro-inflammatory cytokines, but not of the neurodegenerative and severe inflammatory modulator lipocalin-2 (LCN2), was significantly increased, whereas at the late "cachexia stage", the level of LCN2 mRNA was significantly increased along with significant decreases in levels of inhibitory immune checkpoint receptors programmed death receptor-1 (PD-1) and CD112R in hypothalamic microglia. In addition, a high density of activated neurons in the paraventricular nucleus (PVN) of the hypothalamus region and a significant increase in corticosterone secretion were found in cachexia model mice. Related to the cachexia state, released corticosterone was clearly increased in normal mice with specific activation of PVN neurons. A marked decrease in the natural killer cell population was also observed in the spleen of mice with robust activation of PVN neurons as well as mice with cancer cachexia. On the other hand, in vivo administration of LPS in normal mice induced hypothalamic microglia with low expression of inhibitory immune checkpoint receptors. These findings suggest that the induction of cancer cachexia may parallel exacerbation of the hypothalamic inflammatory status with polarization to microglia expressed with low levels of inhibitory immune checkpoint receptors following LPS release from the gut microflora.
NEW MATERIAL:The heterocyclic compound of formula I (R1-R4 are H, hydroxyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, lower alkyl, etc. or adjacent two of them together form methylenedioxy, etc.; W is C or N; R5 is absent when W is N, and is H or halogen when W is C; X is N or CH; Y is group of formula II, formula III, etc.) and its acid addition salt. EXAMPLE:6,7-Dimethoxy-4-[4-( 1,3-dihydro-2-oxo-2H-benzimidazol-1-ylmethyl )piperidino]quinazoline. USE:Useful as a cardiotonic agent having excellent long-acting effect. PREPARATION:The compound of formula I can be produced e.g. by reacting the compound of formula IV (the group of formula V is lower alkylthio, etc.) with the compound of formula HY in a solvent such as acetone, at 0-200 deg.C in the presence of a base.
Humans have important thermoregulatory responses aimed at maintaining body temperature within a narrow range. These responses are driven in part by receptors located in the skin that monitor temperature changes and provide feedback to the central nervous system. Given that skin temperature can affect the physiological responses to heat stress, it is important to accurately measure skin temperature in response to heat stress with and without evaporative (i.e., sweat) and convective (i.e., air flow) cooling. Skin temperature is most often measured on the surface of the skin; however, this temperature can be influenced by other factors such as the local environment. It is unclear how the temperature of the skins surface compares to the temperature within the dermal layer of the skin.

The study team will directly compare skin surface and intradermal temperature responses to heat stress and determine whether these responses area altered by evaporative or convective cooling methods. To accomplish this objective, healthy adults will be exposed to ambient heat stress (no higher than 47°C) with and without evaporative (water sprayed on the skin) and convective (electric fan) cooling. Thermoregulatory responses, inclusive of skin surface and intradermal temperatures, will be assessed throughout the heat trial.
The study is designed as a 6 week case-control follow-up study of 70 AN FE pt. with SCZ and 70 controls matched with regard to age, gender, and parental socio-economic status. All subjects will be examined with a diagnostic interview (SCAN, Schedule for Clinical Assessment in Neuropsychiatry), medical and family history, and physical examination before inclusion. At baseline all subjects will be examined with single photon emission computed tomography (SPECT), MRI, fMRI, psychophysiology, neurocognition. In addition, they will be screened for drugs, genetic testing, and ECG. Patients will further be examined with clinical validated rating scales to measure psychopathology, subjective well-being, and side-effects. After a period of 6 weeks all assessments are repeated. During that period patients will be treated with amisulpride, while healthy controls will receive no treatment at all. Efficacy of antipsychotic treatment will be evaluated after this initial period of 6 weeks. Based on this evaluation it will be decided to either continue the current (amisulpride) antipsychotic treatment, or to switch to aripiprazole. Efficacy of aripiprazole is evaluated on a monthly basis, if the patient does not respond well enough, than the treatment will be adapted individually. Regardless of treatment, all subjects will be re-assessed in the same test battery as mentioned above, except for SPECT and fMRI, after a period of 6, 12, and 24 months. The developement in specific disturbances and the relationship between these will be analysed.
NEW MATERIAL:A compound of formula I (X is H or halogen; R1 is alkyl or polyolefinyl, etc.; R2 is H, alkyl, polyolefinyl, etc. except when X is H and both R1 and R2 are CH3). EXAMPLE:3-(Cinnamyloxy)-17-methylmorphinan. USE:An antitumor agent. PREPARATION:A compound of formula II is dissolved in ethanol and a solution of an alkali hydroxide in an alcohol is added thereto to give an alkali metallic salt, which is reacted with a compound of the formula R1-Y (Y is halogen) to give the compound of formula I (R2 is CH3). Preferably, the reaction temperature is near the boiling point of the solvent, and the reaction time is 3-6hr.
A canine distemper and hard pad disease vaccine is prepared by recovering live virulent virus from dogs exhibiting the clinical manifestations of canine encephalitis caused by canine distemper or hard pad disease virus, inoculating the tissue of embryonic chicks in incubating eggs with an aqueous suspension of said virus and after a period of additional incubation in said eggs preparing an aqueous suspension of the embryonic tissue, similarly inoculating further incubated eggs therewith and repeating the successive passages of the virus through incubating chick embryos until the virus has been adapted to grow therein and has become avirulent to ferrets.  Chick embryos of 6 to 9 days are used, incubation being continued for 4 to 7 days after inoculation.  The incubation temperature is 34 to 40 DEG C., and preferably 37 to 38 DEG C. It is preferred to inoculate the chorioallantoic membrane of the chick embryos.  Before the virus has been adapted to grow in the incubating chick embryos, it is preferred to pass the virus through at least one ferret, in which case, a suspension of the pooled liver and spleen tissues of the infected ferret in e.g. beef heart-infusion broth (beef heart infusion, peptone, sodium chloride, disodium hydrogen phosphate and water) is then used to inoculate the chick embryos.  The vaccine is prepared by grinding the chick embryo tissue containing the avirulent virus with physiological saline, meat infusion broth or water, and purifying in manner known per se to remove tissue and fats.
OBJECTIVE: Elucidating complex ecosystems and molecular features of gallbladder cancer (GBC) and benign gallbladder diseases is pivotal to proactive cancer prevention and optimal therapeutic intervention.
DESIGN: We performed single-cell transcriptome analysis on 230 737 cells from 15 GBCs, 4 cholecystitis samples, 3 gallbladder polyps, 5 gallbladder adenomas and 16 adjacent normal tissues. Findings were validated through large-scale histological assays, digital spatial profiler multiplexed immunofluorescence (GeoMx), etc. Further molecular mechanism was demonstrated with in vitro and in vivo studies.
RESULTS: The cell atlas unveiled an altered immune landscape across different pathological states of gallbladder diseases. GBC featured a more suppressive immune microenvironment with distinct T-cell proliferation patterns and macrophage attributions in different GBC subtypes. Notably, mutual exclusivity between stromal and immune cells was identified and remarkable stromal ecosystem (SC) heterogeneity during GBC progression was unveiled. Specifically, SC1 demonstrated active interaction between Fibro-iCAF and Endo-Tip cells, correlating with poor prognosis. Moreover, epithelium genetic variations within adenocarcinoma (AC) indicated an evolutionary similarity between adenoma and AC. Importantly, our study identified elevated olfactomedin 4 (OLFM4) in epithelial cells as a central player in GBC progression. OLFM4 was related to T-cell malfunction and tumour-associated macrophage infiltration, leading to a worse prognosis in GBC. Further investigations revealed that OLFM4 upregulated programmed death-ligand 1 (PD-L1) expression through the MAPK-AP1 axis, facilitating tumour cell immune evasion.
CONCLUSION: These findings offer a valuable resource for understanding the pathogenesis of gallbladder diseases and indicate OLFM4 as a potential biomarker and therapeutic target for GBC.
Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
NEW MATERIAL:A pyrazine derivative shown by formula I (X is H, halogen, lower alkyl, lower alkoxy or di-lower alkylamino). EXAMPLE:2,3-Bis(p-methoxyphenyl)-5-methylpyrazine. USE:A drug useful as an inhibitor of blood platelet aggregation. Extremely suppressing inhibitory action on blood platelet aggregation derived by arachidonic acid or collagen and useful for preventing especially myocardial infarction, ischemic attach after cerebral apoplexy, thrombosis such as cerebral infarct, etc. Being expected to be useful as anti-inflammatory drug because of inhibitory action on cyclooxygenase. PREPARATION:For example, a benzyl derivative shown by formula II is reacted with a 1,2-diamine derivative shown by formula III in an organic solvent such as ethanol, etc., to give a dihydropyrazine shown by formula IV, which is heated with sulfur at 100-180 deg.C to give a compound shown by formula I.
In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate foam, 0.05% or clobetasol propionate.

In a 90-day repeat-dose toxicity study in rats, topical administration of clobetasol propionate foam at dose concentrations from 0.001% to 0.1% or from 0.03 to 0.3 mg/kg/day of clobetasol propionate resulted in a toxicity profile consistent with long-term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression, and opportunistic fungal and bacterial infections. A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis.

Clobetasol propionate was nonmutagenic in the Ames test, the mouse lymphoma test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test. In the in vivo mouse micronucleus test, a positive finding was observed at 24 hours, but not at 48 hours, following oral administration at a dose of 2,000 mg/kg.

Studies in the rat following subcutaneous administration of clobetasol propionate at dosage levels up to 0.05 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.
A cell, isolated nucleic acid, vector, isolated polypeptide, and method of treating a bacterial infection are provided. The cell includes a modified  Acinetobacter baumannii  cell having a mutation in an  A. baumannii  gene selected from a mutation that occurs when generating mutations in  A. baumanni  using transposon mutagenesis. The isolated nucleic acid includes a sequence expressing a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The vector includes the isolated nucleic acid. The isolated polypeptide includes a lpsB, mffT, or GctA polypeptide comprising at least one nucleic acid mutation. The method of treating a bacterial infection includes administering to a subject an effective amount of an  Acinetobacter baumannii  composition including modified  Acinetobacter baumannii  cell.
Thiols of formula RSH can be used to maintain sufficient cell division in vivo and in vitro, even in the presence of cell poisons. (R is not given). The thiol is pref. L-cysteine, or is a thiol in which the SH gp. is Me-substd., (e.g. L-methionine) or a methylsulphonium cpd. (e.g. S-adenosyl-methionine), or a sulphonic acid such as cysteic acid or tuarine. The thiols are modified by ethanoyl gps. and the aminoacid configuration are stabilised by organic salts, e.g. of zinc. The thiols are used to encourage cell growth and regeneration despite the presence of cell growth and regeneration poisons such as halides and hydrocarbons. The thiols can thus be used in the treatment of Alzheimer's disease (Al poisioning) and against poisoning by fluorine and Paraquet, Dieldrin and Lindane, used as insecticides and pesticides in agriculture and which damages the cytoskeleton. The thiols can be used in vivo to protect healthy or damaged cells against further damage.
AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide \[Casodex\] or flutamide \[Eulexin\]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin \[Coumadin®\]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
Adhesive capsulitis (frozen shoulder), a painful disorder caused by capsular inflammation that results in fibrosis and rigidity of the glenohumeral joint capsule, is characterized by a progressive loss of both active and passive glenohumeral movements. Frozen shoulder can be primary (also known as idiopathic) if there is no underlying cause of disease or it can be secondary. The term "secondary frozen shoulder" is associated with injury, trauma, cardiovascular diseases, hemiparesis, or diabetes.Active release technique and myofascial arm pull technique are both effective treatment options for patients with adhesive capsulitis. These techniques help to improve range of motion and reduce pain by releasing tension and adhesions in the affected area. Active release technique focuses on releasing tension and adhesions in the soft tissues surrounding the affected joint, while the Myofascial arm pull technique aims to improve range of motion by stretching the muscle and fascia in the affected area. By incorporating these techniques into a comprehensive treatment plan, patients of adhesive capsulitis can see significant improvement in their pain, range of motion and disability.

Because the method of treatment is inexpensive, findings of this study could be beneficial in revision of the clinical protocols to manage the patients of adhesive capsulitis.